Opko Health Inc (OPK)

[tomsylver]

Opko's 4Kscore in the long run will prove cost effective

James Mohler talks prostate cancer on CureTalk ( http://prostatecancerinfolink.net/2015/01/22/james-mohler-talks-prostate-cancer-on-curetalk/ )
The "New" Prostate Cancer InfoLink ( http://prostatecancerinfolink.net/2015/01/22/james-mohler-talks-prostate-cancer-on-curetalk/ )

On Tuesday this week, Dr. James L. Mohler of Roswell Park Cancer Institute participated in an hour-long discussion on key issues related to the diagnosis and management of early stage prostate cancer. For those who where unable to listen in live, the entire conversation was recorded and can now be accessed on the CureTalk web site ( http://www.curetalks.com/event/rsvp/Diagnosing-Aggressive-Forms-of-Prostate-Cancer-With-New-Imaging-Tests-and-Biomarkers/153/ ) .

Dr. Mohler is the chairman of the prostate cancer guidelines panel for the National Comprehensive Cancer Network (NCCN). He provided us with a brief introduction to some of the key, recent updates to these guidelines. He then focused on issues surrounding newer forms of test that can be used in the precise detection and prognosis of early stage forms of prostate cancer, such as multi-parametric MRI imaging, new genetic and genomic tests, and other new forms of test such as the Prostate Health Index (phi) and the 4KScore.

Dr. Mohler was at pains to point out that, given what we know today about low-risk prostate cancer, a key goal is the avoidance of unnecessary treatment of men with forms of prostate cancer that are highly unlikely to present a serious risk for men during their lifetime — by avoiding unnecessary biopsies and diagnosis in men at very low risk and by avoiding unnecessary treatment in men diagnosed with low-risk and very low-risk disease. Differentiating between cancers of these types and cancers that present with aggressive features that need treatment is a key issue in the evolution of the management of prostate cancer.

52:30
Excerpt:
Dr. Mohler:
"4Kscore in the long run will prove cost effective"
"Excited about the use of more sophisticated test"
"Test will find the proper space early on in disease and I look forward to that happening"

* Talk Recorded on Jan. 20, 2015, 5 p.m. EST Click Here for Audio Link ( http://www.curetalks.com/event/rsvp/Diagnosing-Aggressive-Forms-of-Prostate-Cancer-With-New-Imaging-Tests-and-Biomarkers/153/ )

Dr. James Mohler
Dr. Mohler earned his medical degree from the Medical College of Georgia and completed residency training in Surgery and Urology at the University of Kentucky Medical Center and a research fellowship in Urologic Oncology at The Johns Hopkins University School of Medicine.Dr. Mohler is licensed by New York and North Carolina, a Diplomate of the National Board of Medical Examiners and the American Board of Urology, and a Fellow of the American College of Surgeons.Dr. Mohler is Chair of the NCCN Prostate Cancer Guideline Committee, Past-President of the Society for Basic Urologic Research and Vice-Chair of the Urology Committee of the Alliance for Clinical Trials in Oncology (formerly CALGB) and is a member of the American Medical Association, American Association for the Advancement of Science, American Association for Cancer Research, American Urological Association and American College of Surgeons.Dr. Mohler’s clinical practice focuses upon prostate cancer and robot-assisted laparoscopic surgery. His laboratory focuses upon the role of the androgen receptor in racial differences in prostate cancer aggressiveness and prostate cancer recurrence during androgen deprivation therapy. He has authored or co-authored more than 200 publications and book chapters, and a book “Androgen Action in Prostate Cancer.” He serves on the editorial board of The Prostate, Journal of the National Comprehensive Cancer Network, Journal of Robotic Surgery, and Therapeutic Advances in Urology, and reviews for several journals including Cancer, Cancer Research, Clinical Cancer Research, Journal of Molecular Endocrinology, Journal of Urology, Oncogene, Science Translational Medicine and Urology.